Qualips has approved the insurance reimbursement price of 53,200,000 yen for Rehart\u24c7, scheduled for insurance listing on September 1, 2026. It is actively expanding sales domestically and internationally.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4894","jir_company_name":"Qualips Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-07-22","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4894-20260722-01.pdf","jir_short_summary":"Qualips has approved the insurance reimbursement price of 53,200,000 yen for Rehart\u24c7, scheduled for insurance listing on September 1, 2026. It is actively expanding sales domestically and internationally.","jir_summary":"### Performance Overview\nQualips announced that the Central Social Insurance Medical Council approved the insurance reimbursement price of 53,200,000 yen for the human (allogeneic) iPS cell-derived cardiac muscle cell sheet Rehart\u24c7, which received conditional and time-limited manufacturing and marketing approval in March 2026. The insurance listing is scheduled for September 1, 2026, enabling domestic sales to commence. There has been considerable inquiry from overseas, and efforts toward global expansion are underway.\n\n### Future Outlook and Impact\nFollowing the insurance listing, sales of Rehart\u24c7 are expected to begin, with a forecast of increased treatment demand domestically and internationally. The specific impact on consolidated results for the fiscal year ending March 2027 is currently under review; however, plans include expanding treatment offerings for patients with severe heart failure while also considering overseas expansion.","jir_financial_highlights":"Insurance Reimbursement Price: 53,200,000 yen (Unknown)\nInsurance Listing Date: September 1, 2026 (Unknown)","jir_category":"","jir_hashtags":"#QualipsInc., #FinancialResults, #JapaneseStocks","jir_key_figures":"Insurance Reimbursement Price: 53,200,000 yen\nInsurance Listing Date: September 1, 2026\nScheduled Sales Start: September 1, 2026","jir_meta_title":"\u3010Qualips\u3011Rehart Insurance Reimbursement Price Determination \uff5c July 2026","jir_meta_description":"Qualips's insurance reimbursement price of 53,200,000 yen for Rehart\u24c7 has been approved, with insurance listing scheduled for September 2026. Domestic and international sales development is accelerating.","jir_og_title":"\u3010Qualips\u3011Rehart Insurance Reimbursement Price Determination \uff5c July 2026","jir_og_description":"Qualips's insurance reimbursement price for Rehart\u24c7 has been approved, with sales scheduled to start in September 2026. Important decision to advance overseas expansion as well.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17194,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-86295","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n